Milestone Pharmaceuticals(US:MIST)2026-03-03 15:12Milestone Pharmaceuticals FY Conference Summary Company Overview - Company: Milestone Pharmaceuticals - Product: CARDAMYST (etripamil), a novel calcium channel blocker approved for the treatment of paroxysmal supraventricular tachycardia (PSVT) [3][4] - Launch Timeline: Product launched in pharmacies in January 2026, with a commercial launch in February 2026 [4] Industry Context - Target Disease: Paroxysmal supraventricular tachycardia (PSVT), characterized by rapid heart rates exceeding 200 beats per minute, affecting over 2 million patients in the U.S. [9][10] - Market Opportunity: Approximately 200,000-300,000 new diagnoses annually, with significant costs associated with emergency department visits and hospital admissions [9][10] - Current Treatment Landscape: Limited options available for acute episodes, with no new treatments introduced in over 30 years [8][9] Product Details - Formulation: Portable nasal spray with two doses for acute episodes [3] - Onset of Action: Rapid onset with a peak concentration (Cmax) in 7 minutes [11] - Shelf Life: 36 months, with a minimum of 18 months in the launch year [12] - Patent Protection: Composition of matter and formulation patents extend through 2042 [12] Commercial Strategy - Sales Force: 60 representatives targeting approximately 10,000 healthcare providers (HCPs) [17] - Market Focus: Engaging cardiologists and primary care physicians who treat patients seeking help for PSVT [11][17] - Pricing Strategy: Wholesale acquisition cost (WAC) set at $1,649, with plans for tiered coverage to ensure affordability for patients [19][20] - Patient Activation: Strategies to engage patients dissatisfied with current treatment options to drive them back into the healthcare system [42][43] Financial Overview - Cash Position: Reasonable cash balance as of September 2025, bolstered by a recent $75 million royalty payment [5] - Market Cap: Approximately $101.6 million, including common shares and pre-funded warrants [30] Pipeline and Future Indications - Next Indication: Atrial fibrillation (AFib) with plans for a Phase III study targeting rapid ventricular rates [26][29] - Market Size for AFib: Estimated to be 3-4 times larger than the PSVT market, with significant hospital visits associated with acute episodes [26][27] Launch Metrics and Expectations - Initial Launch Performance: Early signs of prescription volume growth, with ongoing monitoring of script fill rates and physician engagement [34][38] - Payer Engagement: Active discussions with commercial payers, aiming for coverage within 12-18 months [36][37] - Key Performance Indicators: Focus on generating scripts, physician awareness, and patient coverage metrics [21][22] Challenges and Considerations - Physician Hesitancy: Initial pushback due to lack of awareness and the conservative nature of cardiologists [45][48] - Patient Journey: Many patients experience a lengthy and challenging path to diagnosis and treatment, often leading to dissatisfaction with existing options [50][51] Conclusion Milestone Pharmaceuticals is positioned to capitalize on a significant market opportunity with CARDAMYST, addressing a long-standing gap in the treatment of PSVT. The company's strategic focus on physician engagement, patient activation, and a robust pipeline for future indications like AFib suggests a promising outlook for growth and market penetration.